Skip to main content
Premium Trial:

Request an Annual Quote

Chromatide Closes VC Round with Existing Investors

NEW YORK (GenomeWeb News) — UK-based synthetic polymer company Chromatide said today that it has received an undisclosed second round of financing from Enterprise Ventures and Alliance Fund Managers, both of which invested in it in 2007.

Chromatide, which plans to use the money to continue expanding its IP portfolio, said that since the first investment it has "successfully delivered on a range of technical and commercial" milestones.

CEO Clare Hildred said in a statement that the company is using its expertise to develop a range of new technologies for biomolecule purification, polymer synthesis, chemical processes, and instrument design.

AFM offers loans and equity packages ranging from £3,000 ($4,300) to £4 million to businesses located in Merseyside, UK.

EV is an independent fund manager that provides private equity and venture capital to regional groups located throughout Northern England and the Midlands region.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.